ClinicalTrials.gg
CompletedNCT01448525Updated May 22, 2013Results posted

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

A Phase 4 interventional study of bimatoprost ophthalmic solution 0.03% and bimatoprost vehicle solution in Hypotrichosis, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-05-22.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hypotrichosis by AbbVie — none open to participants now, none under way, none of them phase 3. Hypotrichosis · AbbVie.

Started
2011
with 2 others
Phase 4
3 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Hypotrichosis by AbbVie, this one is one of 3 that started in 2011, is one of 3 in phase 4, and was the 7th registered.

Hypotrichosis

24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.

Browse Hypotrichosis studies →

Open to participants now

None of the 11 studies in Hypotrichosis by AbbVie is open now. The open studies under Hypotrichosis, anywhere →

Who these studies take

Of the 2 Hypotrichosis studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Hypotrichosis by AbbVie as a file.
02

Study summary

The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.

03

Conditions studied

  • Hypotrichosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have inadequate eyelashes
  • Never used prescription eyelash growth products

Exclusion criteria

Exclusion Criteria:

  • No visible eyelashes
  • Permanent eyeliner or eyelash implants
  • Semi-permanent eyelash tint, dye, or extensions within 3 months
  • Over-the-counter eyelash growth products within 6 months
  • Any disease, infection or abnormality of the eye or area around the eye
  • Eye surgery within 3 months, or the anticipated need for eye surgery during the study
  • Unable or unwilling to keep contact lenses out during drug application and for 30 minutes after application
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Active comparator
    bimatoprost ophthalmic solution 0.03%

    One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

    Drug: bimatoprost ophthalmic solution 0.03%

  • Placebo comparator
    bimatoprost vehicle solution

    One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

    Drug: bimatoprost vehicle solution

Interventions

  • One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

    Also known as: LATISSE®

  • Drugbimatoprost vehicle solution

    One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall

    Participants rated their overall eyelash satisfaction by answering Eyelash Satisfaction Questionnaire (ESQ-9) question #3: "Overall, how satisfied are you with your eyelashes?" using a 5-point scale: -2=very unsatisfied (worst), -1=unsatisfied, 0=neutral, 1=satisfied or 2=very satisfied (best). The percentage of participants who rated their satisfaction as 1=satisfied or 2=very satisfied at Week 16 is reported.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score

    The investigator evaluated the patient's overall eyelash prominence using the 4-point GEA scale: 1=minimal (worst), 2=moderate, 3=marked or 4=very marked (best). An at least a 1-grade increase in GEA score indicated improvement.

    Time frame: Baseline, Week 16

07

Results

Posted May 22, 2013

Participant flow

Participant flow — Overall Study
MilestoneBimatoprost Ophthalmic Solution 0.03%Bimatoprost Vehicle Solution
Started4444
Completed4342
Not completed12

Outcome measures

PrimaryPercentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall

Participants rated their overall eyelash satisfaction by answering Eyelash Satisfaction Questionnaire (ESQ-9) question #3: "Overall, how satisfied are you with your eyelashes?" using a 5-point scale: -2=very unsatisfied (worst), -1=unsatisfied, 0=neutral, 1=satisfied or 2=very satisfied (best). The percentage of participants who rated their satisfaction as 1=satisfied or 2=very satisfied at Week 16 is reported.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall
Percentage of participantsBimatoprost Ophthalmic Solution 0.03%Bimatoprost Vehicle Solution
Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall67.47.1
SecondaryPercentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score

The investigator evaluated the patient's overall eyelash prominence using the 4-point GEA scale: 1=minimal (worst), 2=moderate, 3=marked or 4=very marked (best). An at least a 1-grade increase in GEA score indicated improvement.

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score
Percentage of participantsBimatoprost Ophthalmic Solution 0.03%Bimatoprost Vehicle Solution
Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score72.1 ± 0.3719.0 ± 0.43

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimatoprost Ophthalmic Solution 0.03%—0/44 (0%)1/44 (2.3%)
Bimatoprost Vehicle Solution—0/44 (0%)3/44 (6.8%)
Most frequent other events
Most frequent other events
EventBimatoprost Ophthalmic Solution 0.03%Bimatoprost Vehicle Solution
NasopharyngitisInfections and infestations1/443/44

Baseline characteristics

Age Continuous
Age Continuous(Years)Bimatoprost Ophthalmic Solution 0.03%Bimatoprost Vehicle SolutionTotal
Mean49.2 ± 12.650.2 ± 10.549.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Bimatoprost Ophthalmic Solution 0.03%Bimatoprost Vehicle SolutionTotal
Female444488
Male000
08

Study locations

1 site
  • Coral Gables, Florida, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2011
First posted
Oct 7, 2011
Start
Oct 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
May 22, 2013
Last update
May 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01448525
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 7, 2011
Start date
Oct 2011
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
May 22, 2013
Last update
May 22, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimatoprost Ophthalmic Solution

Start the discussion